Neuroscience
Antipsychotic
100%
Dementia Praecox
94%
Psychosis
44%
Dopamine
41%
Brain
40%
Haloperidol
30%
Positron Emission Tomography
26%
Placebo
25%
Positron Emission Tomography
24%
Eicosanoid Receptor
24%
Phosphodiesterase
20%
Dopaminergic
19%
Olanzapine
17%
Risperidone
17%
Tetrahydrocannabinol
16%
Aripiprazole
15%
Negative Syndrome
15%
Magnetic Resonance Imaging
14%
In Vivo
14%
DOPA
12%
Gene
12%
Cannabis
11%
Antidepressant
11%
Receptor Occupancy
11%
Positive Syndrome
10%
Prefrontal Cortex
9%
Agonist
9%
Major Depressive Disorder
8%
Treatment of Schizophrenia
8%
Anterior Cingulate Cortex
8%
Serotonergic
7%
Ventral Striatum
7%
Striatum
7%
Delusion
7%
Functional Magnetic Resonance Imaging
6%
Meta-Analysis
6%
Treatment-Resistant Schizophrenia
6%
Cognitive Function
6%
Gray Matter
6%
Huntington's Disease
6%
Modafinil
6%
Cannabidiol
6%
Anxiety
6%
Predictor
5%
Putamen
5%
Hippocampus
5%
Working Memory
5%
Serotonin
5%
Nucleus Accumbens
5%
Amygdala
5%
Medicine and Dentistry
Typical Antipsychotic
42%
Therapeutic Procedure
41%
Patient
38%
Dopamine Agonist
29%
Psychosis
28%
Symptom
27%
Dopamine
26%
DOPA
18%
Inpatient
18%
Amaurosis
17%
Analysis
16%
Receptor
16%
Carbon 11
15%
Positron Emission Tomography
15%
Treatment Response
14%
Phosphodiesterase
12%
Human
12%
Risperidone
12%
Association
12%
Disease
12%
Placebo
11%
Dopamine Metabolism
11%
Psychosis
11%
Regulatory Mechanism
11%
Gene
10%
Positive and Negative Syndrome Scale
10%
Meta-Analysis
10%
Chemotherapeutic Agent
9%
Drug
9%
Psychiatry
9%
Naxagolide
9%
Apomorphine
9%
Antidepressant
9%
Major Depressive Episode
8%
Predictor
8%
Age
8%
Negative Syndrome
7%
Randomized Controlled Trial
7%
Fluorine-18
7%
Biological Marker
7%
Effect Size
7%
Pathophysiology
6%
Magnetic Resonance Imaging
6%
Drug Therapy
6%
Putamen
6%
Delusion
6%
Ziprasidone
6%
Cannabis
6%
Pharmacogenetics
6%
Combination Therapy
6%
Pharmacology, Toxicology and Pharmaceutical Science
Antipsychotic
93%
Schizophrenia
79%
Dopamine
33%
Receptor
31%
Olanzapine
24%
Placebo
23%
Drug
20%
Risperidone
20%
Blindness
17%
Clozapine
16%
Negative Syndrome
16%
Dopamine Receptor Stimulating Agent
15%
Clinical Trial
15%
Symptom
15%
Haloperidol
13%
Aripiprazole
12%
Psychosis
12%
DOPA
11%
Positive Syndrome
10%
Side Effect
10%
Amisulpride
9%
Biological Marker
8%
Normal Human
8%
Pharmacokinetics
7%
Polypharmacy
7%
Animal
7%
Therapeutic Drug Monitoring
7%
Treatment-Resistant Schizophrenia
7%
Pharmacodynamics
7%
Atypical Antipsychotics
7%
Diseases
6%
Antagonist
6%
Cannabis
6%
Human
6%
Fluorine 18
6%
Partial Agonist
6%
Extrapyramidal Symptoms
5%